Eli Lilly announced it is acquiring biotechnology firm Orna Therapeutics for $2.4 billion in cash, securing a key technology platform to strengthen its pipeline, particularly in the weight-loss and diabetes franchises.
- The acquisition provides Lilly with access to new engineered circular RNA (circRNA) therapies and proprietary lipid nanoparticles.
- The strategic investment was met positively by the market, with Eli Lilly's stock trading up about 1% following the news.